Could a radiation and antibody combo free liver transplant patients from daily pills?
NCT ID NCT07634562
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a combination of total lymphoid irradiation (a type of radiation) and anti-thymocyte globulin (an antibody drug) can help liver transplant recipients safely stop taking immunosuppressive drugs. The study will enroll 12 adults receiving a liver transplant at Stanford University. The goal is to see if this approach can induce 'operational tolerance,' meaning the body accepts the new liver without needing long-term medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-Thymocyte Globulin (ATG) and Total Lymphoid Irradiation (TLI)
What this could lead to
If successful, this could allow liver transplant recipients to stop taking lifelong immunosuppressive drugs, reducing side effects and improving quality of life.
What could go wrong
This is a very early, small trial with only 12 participants, so results may not apply widely. The conditioning regimen carries risks like infection, bone marrow suppression, and graft rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••